Stockreport

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials [Yahoo! Finance]

Aptose Biosciences, Inc. - Common Shares  (APTO) 
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: aptose.com/investors
PDF Trials to test tuspetinib in targeted drug combinations for frontline therapy of molecularly defined sub-groups of newly diagnosed AML and MDS SAN DIEGO and TORONTO, [Read more]